BioSyent Announces Quarterly Dividend for Investors in 2025

Author: Dylan Bailey Updated: 08-21-2025 04:45 PM

BioSyent Reports Quarterly Dividend for Shareholders

BioSyent Inc., a dynamic player in the pharmaceutical field, recently made an announcement that is sure to catch the attention of its shareholders. The company has declared a quarterly dividend of $0.05 per common share. This decision, made by its Board of Directors, reflects BioSyent's commitment to rewarding its investors while continuing its mission in the specialty pharmaceutical sector.

Details of the Dividend Declaration

The quarterly dividend will be payable in Canadian Dollars on September 15, 2025. To be eligible for this dividend, shareholders must be on record as of the close of business on August 29, 2025. This dividend mirrors the amount declared for the previous quarter, indicating stability in the company’s financial performance amid market fluctuations.

Understanding Eligible Dividends

For Canadian investors, it's noteworthy that this dividend qualifies as an 'eligible dividend' for income tax purposes. Such a designation can potentially offer more favorable tax treatment, making it an appealing factor for shareholders looking to maximize their investment returns.

About BioSyent Inc.

Founded with the vision of improving patient outcomes, BioSyent Inc. is a profitable and growth-oriented specialty pharmaceutical company. It operates under the trading symbol “RX” on the TSX Venture Exchange. The focus of BioSyent is to in-license or acquire innovative pharmaceutical products that are not only safe and effective but also backed by a proven track record. The company emphasizes its mission to support healthcare professionals by providing products that contribute to patient care.

Market Presence and Structure

BioSyent markets its offerings through various channels, including community, specialty, and international business units. This diversified approach ensures that their innovative products reach the healthcare professionals who need them the most. The company currently has 11,260,794 common shares outstanding, a figure that reflects its robust market presence.

Keeping Stakeholders Informed

To stay updated on the market performance of BioSyent and to gain insights into the company's financial health, stakeholders are encouraged to visit relevant financial news platforms. A reputable source for market quotes for the TSX Venture Exchange and additional financial information can be found at platforms dedicated to stock trading and investment.

Connect with BioSyent for More Information

For those who wish to dive deeper into the company’s operations or who have inquiries, BioSyent provides contact information for direct communication. Stakeholders can reach out to Mr. René C. Goehrum, the President and CEO, via email at investors@biosyent.com or by phone at 905-206-0013. Additionally, the company’s website offers extensive information about its products and business strategy.

Frequently Asked Questions

What is the announced dividend amount for BioSyent?

BioSyent has announced a quarterly dividend of $0.05 per common share.

When will the dividend be paid?

The dividend will be paid on September 15, 2025.

What is the record date for the dividend?

Shareholders must be recorded by August 29, 2025, to be eligible for the dividend.

What makes this dividend eligible for Canadian tax purposes?

This dividend qualifies as an 'eligible dividend' under Canadian tax law, offering potential tax advantages.

Who can I contact for further information about BioSyent?

You can contact Mr. René C. Goehrum, President and CEO, directly via email or phone for more inquiries related to BioSyent.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.